6-Chloro-5-fluoroindolin-2-one | CAS:100487-74-9

We serve 6-Chloro-5-fluoroindolin-2-one CAS:100487-74-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
6-Chloro-5-fluoroindolin-2-one

Chemical Name:6-Chloro-5-fluoroindolin-2-one
CAS.NO:100487-74-9
Synonyms:6-Chloro-5-fluoroindolin-2-one
6-chloro-5-fluoro-1,3-dihydroindol-2-one
6-Chloro-5-fluoro-1,3-dihydro-2H-indol-2-one
 
Physical and Chemical Properties:
Density 1.5±0.1 g/cm3
Boiling Point 327.2±42.0 °C at 760 mmHg
Melting Point 196-206ºC
Molecular Formula C8H5ClFNO
Molecular Weight 185.583
Flash Point 151.7±27.9 °C
Vapour Pressure 0.0±0.7 mmHg at 25°C
Index of Refraction 1.577
 
Specification:
Appearance:Light red crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 6-Chloro-5-fluoroindolin-2-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-Chloro-5-fluoro-1,3-dihydro-2H-indol-2-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-Chloro-5-fluoro-1,3-dihydro-2H-indol-2-one Use and application,6-Chloro-5-fluoroindolin-2-one technical grade,usp/ep/jp grade.


Related News: You will find the name and amount of the active ingredient contained in the medicine on the package of OTC (over-the-counter) drugs.Lithium bis(trifluoromethanesulphonyl)imide manufacturer Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).2',4'-Dichlorovalerophenone supplier Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).picolinic acid vendor Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).Therefore, the R & D capabilities and registration capabilities of API companies have become the core factors of competition.